Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Funamizu, Naotake ^a   Lacy, Curtis Ray ^b   Fujita, Kaori ^c   Furukawa, Kenei ^a   Misawa, Takeyuki ^a   Yanaga, Katsuhiko ^a   Manome, Yoshinobu ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTIDINE DEAMINASE; GEMCITABINE; KI 67 ANTIGEN; TETRAHYDROURIDINE; TRANSCRIPTION FACTOR E2F1; DEOXYCYTIDINE; DRUG DERIVATIVE; ENZYME INHIBITOR;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG CARCINOMA; PANCREAS CARCINOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; BIOSYNTHESIS; CELL CYCLE CHECKPOINT; DRUG ANTAGONISM; DRUG EFFECT; LUNG TUMOR; PANCREAS TUMOR; TUMOR CELL LINE;

CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTIDINE DEAMINASE; DEOXYCYTIDINE; ENZYME INHIBITORS; HUMANS; LUNG NEOPLASMS; PANCREATIC NEOPLASMS; TETRAHYDROURIDINE;

EID: 84861208319     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037424     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Li D, Xie K, Wolff R, Abbruzzese JL, (2004) Pancreatic cancer. The Lancet 363: 1049-1057.
3. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, et al. (2004) The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 10: 6956-6961.
4. Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, et al. (2011) Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res 17: 5793-5800.
5. Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, et al. (2011) A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 68: 157-164.
6. Neff T, Blau CA, (1996) Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol 24: 1340-1346.
7. Eliopoulos N, Cournoyer D, Momparler RL, (1998) Drug resistance to 5-aza-2′-deoxycytidine, 2′,2′-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Cancer Chemother Pharmacol 42: 373-378.
8. Bardenheuer W, Lehmberg K, Rattmann I, Brueckner A, Schneider A, et al. (2005) Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells. Leukemia 19: 2281-2288.
9. Cohen RM, Wolfenden R, (1971) Cytidine deaminase from Escherichia coli: purification, properties and inhibition by the potential transition state analog 3,4,5,6-tetrahydrouridine. J Biol Chem 246: 7561-7565.
10. Stoller RG, Myers CE, Chabner BA, (1978) Analysis of cytidine deaminase and tetrahydrouridine interaction by use of ligand techniques. Biochem Pharmacol 27: 53-59.
11. Funamizu N, Okamoto A, Kamata Y, Misawa T, Uwagawa T, et al. (2010) Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase? Oncol Rep 23: 471-475.
12. Giovannetti E, Mey V, Loni L, Nannizzi S, Barsanti G, et al. (2007) Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells. Pharmacol Res 55: 343-349.
13. Morita T, Matsuzaki A, Kurokawa S, Tokue A, (2003) Forced expression of cytidine deaminase confers sensitivity to capecitabine. Oncology 65: 267-274.
14. Bouffard DY, Laliberté J, Momparler RL, (1993) Kinetic studies on 2′,2′-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 45: 1857-1861.
15. Beumer JH, Eiseman JL, Parise RA, Florian JA Jr, Joseph E, et al. (2008) Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice. Cancer Chemother Pharmacol 62: 457-464.
16. Beumer JH, Eiseman JL, Parise RA, Joseph E, Covey JM, et al. (2008) Modulation of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine. Clin Cancer Res 14: 3529-3535.
17. Kanno S, Hiura T, Ohtake T, Koiwai K, Suzuki H, et al. (2007) Characterization of resistance to cytosine arabinoside (Ara-C) in NALM-6 human B leukemia cells. Clin Chim Acta 377: 144-149.
18. Ohta T, Hori H, Ogawa M, Miyahara M, Kawasaki H, et al. (2004) Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells. Oncol Rep 12: 1115-1120.
19. Gourdeau H, Bibeau L, Ouellet F, Custeau D, Bernier L, et al. (2001) Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity. Cancer Chemother Pharmacol 47: 236-240.
20. Guo D, Myrdal PB, Karlage KL, O'Connell SP, Wissinger TJ, et al. (2010) Stability of 5-fluoro-2′-deoxycytidine and tetrahydrouridine in combination. AAPS Pharm Sci Tech 11: 247-252.
21. Besnard T, Renée N, Etienne-Grimaldi MC, François E, Milano G, (2008) Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites. J Chromatogr B Analyt Technol Biomed Life Sci 870: 117-120.
22. Gusella M, Pasini F, Bolzonella C, Meneghetti S, Barile C, et al. (2011) Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours. Br J Clin Pharmacol 71: 437-444.
23. Ludovini V, Floriani I, Pistola L, Minotti V, Meacci M, et al. (2011) Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. J Thorac Oncol 6: 2018-2026.
24. Schröder JK, Kirch C, Seeber S, Schütte J, (1998) Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br J Haematol 103: 1096-1103.
25. Sugiyama E, Kaniwa N, Kim SR, Hasegawa R, Saito Y, et al. (2010) Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. Clin Pharmacokinet 49: 549-558.
26. Tibaldi C, Giovannetti E, Tiseo M, Leon LG, D'Incecco A, et al. (2011) Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. Ann Oncol Jun 7. [Epub].
27. Ueno H, Kaniwa N, Okusaka T, Ikeda M, Morizane C, et al. (2009) Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. Br J Cancer 100: 870-873.
28. Camiener GW, (1968) Studies of the enzymatic deamination of ara-cytidine. V. inhibition in vitro and in vivo by tetrahydrouridine and other reduced pyrimidine nucleosides. Biochem Pharmacol 17: 1981-1991.
29. Wong PP, Currie VE, Mackey RW, Krakoff IH, Tan CT, et al. (1979) Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside. Cancer Treat Rep 63: 1245-1249.
30. Ho DH, (1977) Potential advances in the clinical use of arabinosyl cytosine. Cancer Treat Rep 61: 717-722.
31. Beumer JH, Eiseman JL, Gilbert JA, Holleran JL, Yellow-Duke AE, et al. (2011) Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice. Cancer Chemother Pharmacol 67: 421-430.
32. Hilger RA, Kredke S, Hedley D, Moeller JG, Bauer RJ, et al. (2002) ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006. Int J Clin Pharmacol Ther 40: 567-568.
33. Ng SS, Tsao MS, Nicklee T, Hedley DW, (2002) Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 1: 777-783.
34. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, et al. (2002) Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 20: 3815-3825.
35. Picot J, Cooper K, Bryant J, Clegg A, (2011) The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation. Health Technol Assess 15: 1-204.
36. Horn T, (1998) Hydroxyurea-ever more fascinating. Notes Undergr 37: 1-3.
37. Funamizu N, Kamata Y, Misawa T, Uwagawa T, Lacy CR, et al. (2011) Hydroxyurea decreases gemcitabine resistance in pancreatic carcinoma cells with highly expressed ribonucleotide reductase. Pancreas Sep 7. [Epub].
38. Un F, Qi C, Prosser M, Wang N, Zhou B, et al. (2006) Modulating ICBP90 to suppress human ribonucleotide reductase M2 induction restores sensitivity to hydroxyurea cytotoxicity. Anticancer Res 26: 2761-2767.
39. Kaubisch A, Kaleya R, Haynes H, Rozenblit A, Wadler S, (2004) Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors. Cancer Chemother Pharmacol 53: 337-340.
40. O'Byrne KJ, Philip PA, Propper DJ, Braybrooke JP, Saunders MP, et al. (1999) A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma. Ann Oncol 10: 981-983.
41. Navarra P, Preziosi P, (1999) Hydroxyurea: new insights on an old drug. Crit Rev Oncol Hematol 29: 249-255.
42. Knudsen ES, Buckmaster C, Chen TT, Feramisco JR, Wang JY, (1998) Inhibition of DNA synthesis by RB: effects on G1/S transition and S-phase progression. Genes Dev 12: 2278-2292.